Flow cytometry analysis showed that PRMT1 knockdown significantly induced apoptosis in CML CD34+CD38− cells, without an additive or synergistic effect when co‐treated with imatinib (Figure 1F,G). This evidence concerns the gene CD34 and chronic myelogenous leukemia, BCR-ABL1 positive.